Abstract: There is provided a gas solution supply apparatus capable of preventing bubbles from being generated in use at a point-of-use even if gas solution to be provided to a point-of-use has a high concentration. The gas solution supply apparatus 1 includes: a gas dissolving unit 4 that dissolves a source gas in a source liquid to produce a first gas solution; a first gas-liquid separator 10 that stores the first gas solution produced and produces a second gas solution through gas-liquid separation of the first gas solution; a pressure reducer 17 that depressurizes the second gas solution produced in the first gas-liquid separator 10; and a second gas-liquid separator 12 that stores the depressurized second gas solution and produces a third gas solution through gas-liquid separation of the second gas solution. The third gas solution is supplied to a point-of-use.

Abstract: Disclosed are methods and compositions for treating a neurodevelopmental disorder in a subject in need thereof. In some aspects, the method includes administering an effective amount of an agent, wherein administering the agent modulates expression of one or more isoforms of synaptic GTPase-activating protein (SynGAP).

Abstract: Disclosed are methods and compositions for treating a neurodevelopmental disorder in a subject in need thereof. In some aspects, the method includes administering an effective amount of an agent, wherein administering the agent modulates expression of one or more isoforms of synaptic GTPase-activating protein (SynGAP).

Abstract: Disclosed are methods and compositions for treating a neurodevelopmental disorder in a subject in need thereof. In some aspects, the method includes administering an effective amount of an agent, wherein administering the agent modulates expression of one or more isoforms of synaptic GTPase-activating protein (SynGAP).

Abstract: To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein ?, Alcadein ?, or Alcadein ?; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker.

Abstract: To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein ?, Alcadein ?, or Alcadein ?; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker.

Abstract: To provide a peptide obtainable by cleaving an N-terminal region and a C-terminal region of Alcadein ?, Alcadein ?, or Alcadein ?; and capable of being a diagnostic marker for Alzheimer's disease. It is possible to detect Alzheimer's disease at an early stage without burdening subjects to be tested by using the peptide as a diagnostic marker.

Abstract: In order to etch an object to be processed, such as a semiconductor wafer, the object to be processed is placed in a vacuum processing chamber, an etching gas is introduced into the vacuum processing chamber, and electrical power is applied to a pair of electrodes within the vacuum processing chamber by a high-frequency electrical power source. A mixed gas of carbon monoxide and a gas which does not contain hydrogen and which contains at least one element from the group IV elements and at least one element from group VII elements is used as the etching gas. A halogenated carbon gas, typically a fluorocarbon such as C.sub.4 F.sub.8, is used as the gas containing elements from the group IV and group VII elements. The concentration of carbon monoxide in the etching gas could be 50% or more. At least approximately 86% of an inert gas, such as argon, xenon, krypton, or N.sub.2 and O.sub.2 could be added to the etching gas.